Relmada Therapeutics (RLMD) Earnings Date, Estimates & Call Transcripts $0.61 -0.03 (-4.07%) Closing price 04:00 PM EasternExtended Trading$0.66 +0.05 (+8.03%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Relmada Therapeutics Earnings Summary Relmada Therapeutics posted Q1 2025 earnings on May 12, 2025, reporting an EPS of -$0.58, which missed analysts' consensus estimates of -$0.31 by $0.27. With a trailing EPS of -$2.51, Relmada Therapeutics' earnings are expected to grow next year, from ($2.73) to ($0.63) per share. Upcoming Q2 Earnings DateAug. 6After Market ClosesEstimatedConsensus EPS (May. 12) -$0.31 Actual EPS (May. 12) -$0.58 Missed By -$0.27 Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q) Press Release (8-K)RLMD Upcoming EarningsRelmada Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportPowered by Get Relmada Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relmada Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRLMD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Relmada Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.10-$0.10-$0.10Q2 20251-$0.04-$0.04-$0.04Q3 20251-$0.04-$0.04-$0.04Q4 20251-$0.03-$0.03-$0.03 Relmada Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)-------5/12/2025Q1 2025-$0.31-$0.58 -$0.27-$0.58--3/27/2025Q4 2024-$0.70-$0.62+$0.08-$0.62--11/7/2024Q3 2024-$0.65-$0.72 -$0.07-$0.72--8/7/2024Q2 2024-$0.83-$0.59+$0.24-$0.59--5/8/2024Q1 2024-$0.90-$0.72+$0.18-$0.72--3/19/2024Q4 2023-$0.88-$0.84+$0.04-$0.84--11/8/2023Q3 2023-$0.95-$0.73+$0.22-$0.73--8/8/2023Q2 2023-$0.92-$0.84+$0.08-$0.84-- Relmada Therapeutics Earnings - Frequently Asked Questions When is Relmada Therapeutics' earnings date? Relmada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on RLMD's earnings history. Did Relmada Therapeutics beat their earnings estimates last quarter? In the previous quarter, Relmada Therapeutics (NASDAQ:RLMD) missed the analysts' consensus estimate of ($0.31) by $0.27 with a reported earnings per share (EPS) of ($0.58). Learn more on analysts' earnings estimate vs. RLMD's actual earnings. How can I listen to Relmada Therapeutics' earnings conference call? The conference call for Relmada Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Relmada Therapeutics' conference call transcript? The conference call transcript for Relmada Therapeutics' latest earnings report can be read online. Read Transcript How much profit does Relmada Therapeutics generate each year? Relmada Therapeutics (NASDAQ:RLMD) has a recorded net income of -$79.98 million. RLMD has generated -$2.51 earnings per share over the last four quarters. What is Relmada Therapeutics' EPS forecast for next year? Relmada Therapeutics' earnings are expected to grow from ($2.73) per share to ($0.63) per share in the next year. More Earnings Resources from MarketBeat Related Companies eXoZymes Earnings Date Cabaletta Bio Earnings Date IGM Biosciences Earnings Date Pliant Therapeutics Earnings Date Zura Bio Earnings Date ESSA Pharma Earnings Date Quince Therapeutics Earnings Date Surrozen Earnings Date Immix Biopharma Earnings Date Acumen Pharmaceuticals Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong This page (NASDAQ:RLMD) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts